Why the study?
Does beta-blocker therapy improve clinical outcomes and mortality in patients with congestive heart failure?
Does beta-blocker therapy improve clinical outcomes and mortality in patients with congestive heart failure?
This review highlights that beta-blockers, when added to conventional therapy, provide significant clinical benefits and improve survival in patients with congestive heart failure.
Strengthens case for beta-blockers in CHF; leaves open optimal integration with contemporary GDMT.
Experience accumulated from several large trials strongly suggest that beta-blockers should be used for the management of congestive heart failure (CHF). Beta-blockade should be added to conventional therapy such as diuretics, ACE inhibitors, and digoxin, as this was the approach used in the major trials. It is appropriate to treat patients with mild, moderate and, when stable, severe CHF. The benefits obtained include improvements in left ventricular function, reductions in symptoms and morbidity, improvement of quality of life, and delay of clinical progression, reflected by a reduced need for hospitalization and a reduction in mortality. Beta-blockers are much better tolerated, when used appropriately in selected patients, than was previously supposed.
No takes yet. Share an insight, caveat, or question.
Cleland et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: